K-Bio Technology Exports Top 17 Trillion Won as Hanmi Licenses Obesity Drug to Roche

The Quick Take

• Korean pharma-biotech technology exports exceeded 17.2 trillion won in 2026, reaching 64% of 2025 full-year total
• Hanmi Pharma licensed obesity drug HM17321 to Roche Genentech for approximately 3.5 trillion won
• CHA Biotech secured 3.15 billion won in government K-HERO R&D funding over 3.5 years for cell therapy

South Korea pharmaceutical and biotech sector has surpassed 17.2 trillion won in technology export licensing deals through mid-2026, already reaching 64% of the full-year 2025 total of 26.9 trillion won. The milestone reflects a sustained pipeline of licensing deals with global pharmaceutical majors, with Hanmi Pharma licensing its novel obesity drug candidate HM17321 — a non-incretin UCN2 analogue targeting weight loss without the muscle loss associated with GLP-1 class drugs — to Roche Genentech for approximately 3.5 trillion won. CHA Biotech separately secured government K-HERO program funding of 3.15 billion won over 3.5 years to advance its MSC cell therapy and gene therapy platforms toward global clinical-stage development.

The K-Bio licensing momentum has direct implications for the broader global obesity and metabolic disease drug market, where Hanmi HM17321 as a UCN2 analogue would compete with Novo Nordisk GLP-1 and Eli Lilly tirzepatide classes if it advances through Genentech clinical development. The novelty of the non-incretin mechanism provides a differentiated efficacy profile that could address the muscle-wasting side effect gap in the GLP-1 class, potentially expanding the addressable patient population. For Korean biotech valuations, each successive licensing deal at scale validates the sector R&D pipeline quality and supports premium valuation multiples for companies with next-generation platform assets.

Watch Phase 1 and Phase 2 clinical timelines for HM17321 under Genentech sponsorship as the key de-risking milestone that validates the licensing valuation. CHA Biotech government K-HERO selection confirms government willingness to fund next-generation cell and gene therapy platforms, signalling regulatory and funding tailwinds for the broader Korean cell therapy ecosystem. The macro variable is the global obesity drug market size trajectory — if GLP-1 market growth accelerates faster than current estimates, the competitive urgency for non-incretin alternatives like HM17321 increases and could attract additional licensing or partnership interest from other global majors.

Synthesized from 2 sources.